A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer.

Kathryn A Gold; J Jack Lee; Nusrat Harun; Ximing Tang; Justina Price; Jitesh D Kawedia; Hai T Tran; Jeremy J Erasmus; George R Blumenschein; William N William; Ignacio I Wistuba; Faye M Johnson

首页> 外文期刊>The oncologist >A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer.

【24h】

A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer.

机译：I / II期研究结合埃洛替尼和达沙替尼治疗非小细胞肺癌。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The combination of erlotinib and dasatinib is safe and feasible in NSCLC. The results of this study do not support use of this combination in molecularly unselected NSCLC.

机译：厄洛替尼和达沙替尼的组合在NSCLC中是安全可行的。这项研究的结果不支持在分子非选择的NSCLC中使用这种组合。

著录项

来源
《The oncologist》 |2014年第10期|共2页
作者
Kathryn A Gold; J Jack Lee; Nusrat Harun; Ximing Tang; Justina Price; Jitesh D Kawedia; Hai T Tran; Jeremy J Erasmus; George R Blumenschein; William N William; Ignacio I Wistuba; Faye M Johnson;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. [J] . Kathryn A Gold, J Jack Lee, Nusrat Harun, The oncologist . 2014,第10期

机译：I / II期研究结合埃洛替尼和达沙替尼治疗非小细胞肺癌。
2. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. [J] . Haura EB, Tanvetyanon T, Chiappori Journal of Clinical Oncology . 2010,第8期

机译：Src抑制剂达沙替尼联合厄洛替尼治疗晚期非小细胞肺癌的I / II期研究。
3. A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer. [J] . Akerley W, Boucher KM, Bentz JS, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2009,第2期

机译：厄洛替尼的II期研究作为IIIB-IV期非小细胞肺癌患者的初始治疗。
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. A Study of Erlotinib Monotherapy and in Combination with Pembrolizumab in Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer [D] . Liu, Qiong. 2021

机译：Erlotinib单疗法和蛋白质在先前未处理阶段I-IIIA非小细胞肺癌中的研究
6. A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer [O] . Kathryn A. Gold, J. Jack Lee, Nusrat Harun, 2014

机译：埃罗替尼和达沙替尼联合用于非小细胞肺癌的I / II期研究
7. P1-261: Resource utilization and therapy costs for patients with advanced stage IIIB/IV non-small cell lung cancer. Retrospective data from patients participating in the erlotinib phase IV study (TRUST) in Finland [O] . Mali Pekka, Karjalainen Eeva-Maija, Knuuttila Aija, 2007

机译：P1-261：晚期IIIB / IV期非小细胞肺癌患者的资源利用和治疗费用。来自芬兰埃罗替尼IV期研究（TRUST）的患者的回顾性数据

A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer.

摘要

著录项

相似文献

相关主题

期刊订阅